Selection of Alternative CYP3A4 Probe Substrates for Clinical Drug Interaction Studies Using In Vitro Data and In Vivo Simulation

@article{Foti2010SelectionOA,
  title={Selection of Alternative CYP3A4 Probe Substrates for Clinical Drug Interaction Studies Using In Vitro Data and In Vivo Simulation},
  author={Robert S. Foti and Dan A. Rock and Larry C. Wienkers and Jan L. Wahlstrom},
  journal={Drug Metabolism and Disposition},
  year={2010},
  volume={38},
  pages={981 - 987}
}
Understanding the potential for cytochrome P450-mediated drug-drug interactions (DDIs) is a critical step in the drug discovery process. DDIs of CYP3A4 are of particular importance because of the number of marketed drugs that are cleared by this enzyme. In response to studies that suggested the presence of several binding regions within the CYP3A4 active site, multiple probe substrates are often used for in vitro CYP3A4 DDI studies, including midazolam (the clinical standard), felodipine… Expand
Prediction of CYP2D6 Drug Interactions from In Vitro Data: Evidence for Substrate-Dependent Inhibition
TLDR
The in vivo sensitivities of the clinically relevant CYP2D6 substrates desipramine, dextromethorphan, and metoprolol were determined on the basis of literature drug-drug interaction (DDI) outcomes and it was indicated that the marked decrease in inhibition potency observed for the metoprool-quinidine interaction in vitro translated to the in vivo situation. Expand
Evaluation of CYP2C8 Inhibition In Vitro: Utility of Montelukast as a Selective CYP2C8 Probe Substrate
TLDR
In vitro phenotyping indicated that montelukast is an appropriate probe for CYP2C8 inhibition studies, and Comparisons of the predictions with clinical data coupled with the potential liabilities of other CYP 2C8 probes suggest that Montelukasts is anappropriate CYP1C8 probe substrate to use for the in vivo situation. Expand
Quantitative Analysis of Complex Drug-Drug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data.
TLDR
The results based on in vitro Ki values for transport and metabolism suggest the possibility of a bottom-up approach with in Vitro inhibition data for the prediction of complex DDIs using unified PBPK models and in  vitro fm value of a substrate for multiple enzymes should be considered carefully for the Prediction. Expand
Prediction of cytochrome P450-mediated drug clearance in humans based on the measured activities of selected CYPs
TLDR
It is suggested that measuring the activity of CYP1A2, 2B6, 2C9, and 2C19 allowed us to accurately predict CYP2A6-, 2C8-, 2D6-,2E1-, and 3A4/5-mediated activities in vitro and in vivo and may possibly be helpful for the assessment of an individual’s drug metabolic profile. Expand
Functional Characterization of 40 CYP3A4 Variants by Assessing Midazolam 1′-Hydroxylation and Testosterone 6β-Hydroxylation
TLDR
The findings offer insight into the mechanism underlying interindividual differences in CYP3A4-dependent drug metabolism and provide guidance for improving drug administration protocols by considering the information on CYP 3A4 genetic polymorphisms. Expand
Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment.
TLDR
The number of drugs that are proven or likely major perpetrators of CYP-mediated PK- DDIs is relatively small, and current clinical decision support on PK-DDIs is inconsistent with the published evidence and can be improved using simple criteria. Expand
Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients.
TLDR
In conclusion, in vitro data are useful as a first indication for potential pharmacokinetic drug interactions with CAM, but the discrepancies between in vitro and clinical results for milk thistle and P. ginseng show that clinical studies are required for confirmation of potential interactions. Expand
CYP3A Time-Dependent Inhibition Risk Assessment Validated with 400 Reference Drugs
TLDR
The TDI potential for 400 registered drugs is evaluated using a high-throughput assay format based on determination of the inactivation rate (kobs) at a single concentration of test compound (10 μM) using a new assay format highlighted by comparison with data generated using the IC50 shift assay. Expand
Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data.
TLDR
The results of this study suggest that inhibition of multiple clearance pathways in vivo is clinically relevant, and the risk of DDIs with object drugs may be best evaluated in studies using multi-P450 inhibitors. Expand
Characterization of the Active Site Properties of CYP 4 F 12 s
Cytochrome P450 4F12 is a drug-metabolizing enzyme that is primarily expressed in the liver, kidney, colon, small intestine, and heart. The properties of CYP4F12 that may impart an increasedExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 30 REFERENCES
CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.
TLDR
It is recommended that multiple CYP3A4 probes, representing each substrate group, are used for the in vitro assessment of CYP 3A4-mediated drug interactions. Expand
CYP2C19 Inhibition: The Impact of Substrate Probe Selection on in Vitro Inhibition Profiles
TLDR
Predictions of in vivo inhibition potency based on the in vitro data suggest that most drug-drug interactions will be identified by either (S)-mephenytoin or omeprazole, although the expected magnitude of the interaction may vary depending on the chosen substrate probe. Expand
CYP2C9 Inhibition: Impact of Probe Selection and Pharmacogenetics on in Vitro Inhibition Profiles
TLDR
Both genotype and choice of probe substrate must be considered when attempting to predict potential CYP2C9 drug-drug interactions from in vitro data. Expand
CYP 3 A 4 Substrate Selection and Substitution in the Prediction of Potential Drug-Drug Interactions
The complexity of in vitro kinetic phenomena observed for CYP3A4 substrates (homoor heterotropic cooperativity) confounds the prediction of drug-drug interactions, and an evaluation of alternativeExpand
Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates.
TLDR
BFC and DBF appear more suitable as an initial screen for CYP3A4 inhibition, whereas the rank order of sensitivity among the fluorometric substrates varied among the individual inhibitors, on average, BFC dealkylation was the most sensitive to inhibition, while BQ dealkYLation was least sensitive. Expand
CYP3A4 Substrate Selection and Substitution in the Prediction of Potential Drug-Drug Interactions
TLDR
Comparison of simple and multisite mechanistic models and interaction prediction accuracy for each of the in vitro probes indicated that midazolam and quinidine in vitro data provided the best assessment of a potential interaction, with the lowest bias and the highest precision of the prediction. Expand
IMPACT OF PARALLEL PATHWAYS OF DRUG ELIMINATION AND MULTIPLE CYTOCHROME P450 INVOLVEMENT ON DRUG-DRUG INTERACTIONS: CYP2D6 PARADIGM
TLDR
It is concluded that incorporating parallel pathways provides a valuable step forward in making quantitative predictions of drug-drug interactions from in vitro data. Expand
The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions
TLDR
Findings support the conclusion that P450 in vitro inhibition data are valuable in designing clinical DDI study strategies and can be used to predict the magnitudes of DDI. Expand
In vitro cytochrome P450 inhibition data and the prediction of drug‐drug interactions: Qualitative relationships, quantitative predictions, and the rank‐order approach
TLDR
The possibility of extrapolation of results of clinical DDI studies with 1 drug known to be leared by a particular drug-metabolizing enzyme to ther drugs that are cleared by that same enzyme is ttractive. Expand
Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis.
TLDR
Quantitative correlations of AUC ratios between four CYP3A inhibitors (fluconazole, erythromycin, verapamil, diltiazem) and ketoconazole were uncovered andSimvastatin and buspirone were consistently more sensitive than midazolam, independent of the inhibitor. Expand
...
1
2
3
...